regenerationnet - the network for regenerative biology

Looking for the Fountain of Youth? Cut Your Calories, SLU Research Suggests

Thu, 03 Jul 2008 17:19:06 +0200

Teaser:

Want to slow the signs of aging and live longer? New Saint Louis University research suggests cutting back on calories could be a promising strategy.

Source: Saint Louis University

Gene Directs Stem Cells To Build The Heart

Thu, 03 Jul 2008 17:17:44 +0200

Teaser:

Washington University School of Medicine in St. Louis researchers have shown that they can put mouse embryonic stem cells to work building the heart, potentially moving medical science a significant step closer to a new generation of heart disease treatments that use human stem cells.

New Source of Heart Stem Cells Discovered

Wed, 02 Jul 2008 10:42:30 +0200

Teaser:

Harvard Stem Cell Institute(HSCI) researchers at Children’s Hospital Boston are continuing to document the heart’s earliest origins. Now, they have pinpointed a new, previously unrecognized group of stem cells that give rise to cardiomyocytes, or heart muscle cells. These stem cells, located in the surface of the heart, or epicardium, advance the hope of being able to regenerate injured heart tissue.

New Source of Heart Stem Cells Discovered

Wed, 02 Jul 2008 10:42:30 +0200

Teaser:

Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan™ in Alzheimer's Disease

Wed, 02 Jul 2008 10:38:32 +0200

Teaser:

Myriad Genetics, Inc. (NASDAQ: MYGN) announced results of the Act-Earli-AD trial, an 18-month Phase 3 study of Flurizan (tarenflurbil) in patients with mild Alzheimer’s disease. The study did not achieve statistical significance on either of its primary endpoints — cognition and activities of daily living.

Alzheimer's Drug May Prevent Brain Damage in Preemies

Tue, 01 Jul 2008 15:59:44 +0200

Teaser:

Scientists at Children’s Hospital Boston in a study published in The Journal of Neuroscience say they used memantine (brand name Namenda) to stop strokes‚Äîthat would result in learning difficulties, behavioral problems and faulty motor function‚Äîin rats. The researchers hope to receive permission sometime in the next five years to test their new treatment in premature babies who suffer strokes.

Researchers Link Early Stem Cell Mutation to Autism

Tue, 01 Jul 2008 15:56:56 +0200

Teaser:

In a breakthrough scientific study published today in the Proceedings of the National Academy of Sciences, scientists at the Burnham Institute for Medical Research have shown that neural stem cell development may be linked to Autism. The study demonstrated that mice lacking the myocyte enhancer factor 2C (MEF2C) protein in neural stem cells had smaller brains, fewer nerve cells and showed behaviors similar to those seen in humans with a form of autism known as Rett Syndrome.

Nerve Cells Derived from Embryonic Stem Cells and Transplanted into Mice May Lead to Improved Brain Treatments

Tue, 01 Jul 2008 15:54:27 +0200

Teaser:

Scientists at the Burnham Institute for Medical Research have, for the first time, genetically programmed embryonic stem (ES) cells to become nerve cells when transplanted into the brain, according to a study published today in The Journal of Neuroscience. The research, an important step toward developing new treatments for stroke, Alzheimer’s, Parkinson’s and other neurological conditions showed that mice afflicted by stroke showed tangible therapeutic improvement following transplantation of these cells. None of the mice formed tumors, which had been a major setback in prior attempts at stem cell transplantation.

BioStar Second Announcement - Dr. Stephen Minger to Hold Opening Lecture

Mon, 30 Jun 2008 12:30:22 +0200

Teaser:

The Plenary Opening Lecture for the 2008 BioStar Congress will be held by Dr. Stephen Minger. Dr. Minger currently holds the position as Director of King’s Stem Cell Biology Laboratory in the Wolfson Centre for Age-Related Diseases at the King’s College London. Over the last 15 years, his research group has worked with a wide range of somatic cell populations, as well as mouse and human embryonic stem (EM)cells. In 2002, Dr Minger was awarded one of the first two licenses granted by the UK Human Fertilisation and Embryology Authority for the derivation of human E7S cells. We hope you can join us at the BioStar Congress to learn more about this exciting new research.

Stanford Researchers Get Stem Cell Grants for $5.6 Million

Mon, 30 Jun 2008 10:31:48 +0200

Teaser:

Stanford University School of Medicine researchers received approximately $5.6 million on June 27 from the California Institute for Regenerative Medicine in awards designed to support the creation of new pluripotent human stem cell lines. All four of Stanford’s applicants were funded.

BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative

Sat, 28 Jun 2008 06:17:31 +0200

Teaser:

BioTime, Inc., (OTCBB:BTIM) and its wholly-owned subsidiary Embryome Sciences, Inc. announced today the launch of Embryome.com and the International Embryome Initiative, an international collaboration with scientists around the world to create the first systematic map of all the cell types derived from human embryonic stem cells.

Access Pharmaceuticals presents new data at International Symposium showing Company's Angiolix® monoclonal antibody has potential to treat cancer by attacking cancer stem cells

Sat, 28 Jun 2008 06:18:37 +0200

Teaser:

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that the Company gave an oral presentation yesterday on its monoclonal antibody product,Angiolix®, at the 7th International Congress on Recombinant Antibodies, held in Dublin, Ireland. Dr. Agamemnon Epenetos, Access’ Chief Scientific Officer – Europe, presented data showing that Angiolix has the potential to prevent the growth of cancer stem cells.

SurModics Announces Initiation by Merck & Co., Inc. of Phase IIb Clinical Trial for I-vation(TM) TA

Fri, 27 Jun 2008 10:16:17 +0200

Teaser:

SurModics, Inc., a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the initiation by Merck & Co., Inc. of a Phase IIb clinical trial to evaluate the safety and efficacy of SurModics’ I-vation(TM) TA in patients with diabetic macular edema. The initiation of this Phase IIb trial triggers a milestone payment of $9 million from Merck to SurModics under the companies’ License and Research Collaboration Agreement announced in June 2007.

Nerve Cells Derived from Embryonic Stem Cells and Transplanted into Mice May Lead to Improved Brain Treatments

Sat, 28 Jun 2008 06:37:07 +0200

Teaser:

Osiris Therapeutics Announces $2 Million Milestone Payment for Clinical Progress of a Stem Cell Therapy for Type 1 Diabetes

Sat, 28 Jun 2008 06:22:45 +0200

Teaser:

Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has achieved $2 million in milestone payments from the Juvenile Diabetes Research Foundation (JDRF) for progress made on a Phase II clinical trial evaluating Prochymal, a mesenchymal stem cell (MSC) therapy, for patients recently diagnosed with type 1 diabetes. The payments were triggered when Osiris accomplished certain clinical and regulatory milestones including initiating patient treatments.